Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries
Geron Corporation - Common Stock
(NQ:
GERN
)
2.570
-0.060 (-2.28%)
Streaming Delayed Price
Updated: 4:00 PM EST, Feb 21, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
8,958,592
Open
2.635
Bid (Size)
2.570 (20)
Ask (Size)
2.640 (3)
Prev. Close
2.630
Today's Range
2.555 - 2.660
52wk Range
1.690 - 5.340
Shares Outstanding
508,766,846
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Geron to Participate at Upcoming Investor Conferences in March 2025
February 21, 2025
From
Geron Corporation
Via
Business Wire
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 19, 2025
From
Geron Corporation
Via
Business Wire
Performance
YTD
-28.61%
-28.61%
1 Month
-14.90%
-14.90%
3 Month
-37.32%
-37.32%
6 Month
-43.64%
-43.64%
1 Year
+31.12%
+31.12%
More News
Read More
4 Analysts Assess Geron: What You Need To Know
February 18, 2025
Via
Benzinga
Geron to Announce Fourth Quarter and Full-Year 2024 Financial Results on February 26, 2025
February 03, 2025
From
Geron Corporation
Via
Business Wire
Analyst Scoreboard: 4 Ratings For Geron
December 10, 2024
Via
Benzinga
Analyst Ratings For Geron
November 05, 2024
Via
Benzinga
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 21, 2025
From
Geron Corporation
Via
Business Wire
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 19, 2024
From
Geron Corporation
Via
Business Wire
Geron Announces Positive CHMP Opinion for RYTELO™ (imetelstat) for the Treatment of Adults with Transfusion-Dependent Anemia due to Lower-Risk MDS
December 13, 2024
From
Geron Corporation
Via
Business Wire
Geron Announces New IMerge Analyses Presented at ASH Suggesting Clinical Activity of RYTELO™ (imetelstat) in Patients with Lower-Risk MDS Regardless of Type or Number of Prior Therapies
December 10, 2024
From
Geron Corporation
Via
Business Wire
Geron Announces Phase 1 Findings from Two-Part IMproveMF Study Presented at ASH Suggesting Tolerability of RYTELO™ (imetelstat) in Combination with Ruxolitinib as Frontline Therapy in Patients with Myelofibrosis
December 10, 2024
From
Geron Corporation
Via
Business Wire
Geron to Participate in the 7th Annual Evercore ISI HealthCONx Conference
November 27, 2024
From
Geron Corporation
Via
Business Wire
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 21, 2024
From
Geron Corporation
Via
Business Wire
Geron Corporation Announces Appointment of Joseph Eid, M.D. as Executive Vice President, Research and Development
November 11, 2024
From
Geron Corporation
Via
Business Wire
Geron to Participate in the Stifel 2024 Healthcare Conference
November 11, 2024
From
Geron Corporation
Via
Business Wire
Geron (GERN) Q3 2024 Earnings Call Transcript
November 07, 2024
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Royalty Pharma to Acquire Royalty Interest in Geron’s RYTELO for $125 Million
November 07, 2024
From
Royalty Pharma plc
Via
GlobeNewswire
Geron Corporation Announces Up to $375 Million in Funding with Royalty Pharma and Pharmakon Advisors
November 07, 2024
From
Geron Corporation
Via
Business Wire
Geron Corporation Reports Third Quarter 2024 Financial Results and Recent Business Highlights
November 07, 2024
From
Geron Corporation
Via
Business Wire
Geron Announces New Data to be Presented at Upcoming ASH Annual Meeting Highlighting the Potential of RYTELO™ (imetelstat) in Myeloid Hematologic Malignancies
November 05, 2024
From
Geron Corporation
Via
Business Wire
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 17, 2024
From
Geron Corporation
Via
Business Wire
Geron to Announce Third Quarter 2024 Financial Results on November 7, 2024
October 15, 2024
From
Geron Corporation
Via
Business Wire
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 19, 2024
From
Geron Corporation
Via
Business Wire
Geron Corporation Announces Appointment of Jim Ziegler as Chief Commercial Officer
September 09, 2024
From
Geron Corporation
Via
Business Wire
Why Recursion Pharmaceuticals Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
September 03, 2024
Via
Benzinga
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.